1. Scrip
  2. >>Focus On Asia
  3. >>China

ESMO: Positive Results Buoy Chinese Oncology Developers' Global Hopes

 
• By Dexter Jie Yan

Promising new clinical results presented at ESMO are likely to help several Chinese firms gain traction to take their new drug candidates into global markets, including the US.

Encouraging trial results help buoy Chinese drug maker's hopes for entry into the US market.
Encouraging trial results buoy Chinese companies' US entry hopes • Source: Shutterstock

A plethora of positive results from Phase III multi-regional clinical trials sponsored by Chinese firms specializing in oncology are buoying hopes for regulatory approvals and globalization ambitions.

It is notable that all the studies reported by the companies at the European Society for Medical Oncology (ESMO) Congress...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.